AXSM Stock — Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. (AXSM)

Updated October 16, 2026.

AXSM is a Stock. Total return is 1697.9% over the past 10.9 years, 1360.1 points ahead of SPY at 337.8%.

Axsome Therapeutics is a biopharmaceutical company that develops and commercializes novel therapies for central nervous system disorders. Its commercial product portfolio includes Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness in narcolepsy and sleep apnea patients, and Symbravo for acute migraine treatment, alongside a pipeline of investigational candidates in development for conditions including Alzheimer's disease agitation, smoking cessation, and fibromyalgia. The company does not currently have an established distribution program.

AXSM performance versus SPY

Price and return data through 2026-10-16.

Total return is 1697.9% over the past 10.9 years, 1360.1 points ahead of SPY at 337.8%. Over the past year its total return — price change plus distributions reinvested — is 25.7%. Its deepest 1-year drawdown was 38.7%.

AXSM key facts

Asset type

Stock

Asset class

Equity

Inception date

11/19/2015

Distribution frequency

None

Last close

$157.14 (as of 2026-10-16)

Market cap

$8,231,121,741

Average volume

873075.0

Beta

0.853

Payout ratio

0.0%

Forward P/E

32.1543

EPS

$-3.74

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AXSM risks and drawbacks

The deepest 1-year drawdown on record here is 38.7%.

Who may consider AXSM — and who may not

It is a weaker fit for investors who need monthly cash flow (AXSM does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on AXSM

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions